CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Return to article

Table 1 Cell cycle analysis of prostate cancer cell lines treated with 15d-PGJ2

Cells were treated with 2.5 and 10 µM 15d-PGJ2 for 24 and 48 h and then analyzed by FACS. n = 4 for 10 µM 15d-PGJ2 treatment and n = 2 for 2.5 µM 15d-PGJ2 treatment. Values are mean ± SD.

24 h

48 h

G0/G1 S G2/M G0/G1 S G2/M

10 µM J2 72.48 ± 0.71 10.83 ± 0.07 16.70 ± 0.78 80.48 ± 1.71 5.88 ± 0.24a 13.64 ± 1.47
LNCaP
2.5 µM J2 71.89 9.53 18.59 75.44 7.14 17.43
Control 72.11 ± 2.08 3.83 ± 0.23 24.07 ± 1.86 78.18 ± 0.84 2.11 ± 0.23 19.71 ± 0.62
10 µM J2 50.43 ± 0.24 36.44 ± 0.55 13.13 ± 0.31 51.27 ± 0.98 33.46 ± 0.40 15.28 ± 1.38
PC-3
2.5 µM J2 47.25 31.07 21.69 48.23 37.75 14.03
Control 55.33 ± 0.48 24.52 ± 0.18 20.16 ± 0.6 53.26 ± 0.49 31.66 ± 0.04 15.08 ± 0.45
10 µM J2 42.04 ± 0.17 25.38 ± 3.10 32.58 ± 3.26 37.00 ± 4.59 34.82 ± 22.7 28.19 ± 18.1
DU145
2.5 µM J2 35.89 42.23 21.88 49.85 14.73 35.43
Control 54.67 ± 1.04 20.24 ± 1.17 20.10 ± 0.12 59.15 ± 0.34 4.34 ± 4.57 36.51 ± 4.24

a P <= 0.05 versus control.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation